US OptionsDetailed Quotes

ASLN250117P2500

Watchlist

0.00
0.000.00%

15min DelayClose Dec 10 09:30 ET

0.00High0.00Low

Aslan Pharmaceuticals Stock Discussion

Dragana

Aug 5 05:25

$Aslan Pharmaceuticals (ASLN.US)$ I lost money and everything is practically deleted is died 🤔😱

MDR81

Jul 22 08:47

$Aslan Pharmaceuticals (ASLN.US)$ what happened here? why trading not opened since last week?

Trytosaveabit

Jul 17 06:26

Grrrr! News

$Aslan Pharmaceuticals (ASLN.US)$ Press Release: ASLAN Pharmaceuticals Announces It Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and Is Commencing Steps to Place Itself Into Voluntary Liquidation
Dow Jones· 1 min ago

152243478

Jul 15 18:08

$Aslan Pharmaceuticals (ASLN.US)$ dont think this will recover

Abela

Jul 15 08:22

$Aslan Pharmaceuticals (ASLN.US)$ no one cares for retail traders

Trytosaveabit

Jul 15 06:35

Oh no! Ouch

$Aslan Pharmaceuticals (ASLN.US)$ ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal
5 MINUTES AGO, 7:30 AM EDT
VIA GLOBENEWSWIRE

152243478

Jul 9 02:55

$Aslan Pharmaceuticals (ASLN.US)$ any updates on this company??

Stock Region

May 21 15:50

Pharmaceutical Company Reveals Major Translational Data For COPD Treatment

ASLAN Pharmaceuticals Presents Groundbreaking Data on Eblasakimab in COPD at ATS 2024 International Conference.
ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company dedicated to developing innovative treatments for patients, has announced a significant late-breaking poster presentation at the American Thoracic Society (ATS) International Conference 2024 in San Diego, Californ...

Trytosaveabit

May 9 06:15

Update! Note dates!

$Aslan Pharmaceuticals (ASLN.US)$ Anticipated upcoming milestones
•Late breaking poster presentation of positive translational data from a head-to-head study of eblasakimab versus dupilumab in a human tissue model of COPD at the American Thoracic Society International Conference 2024 on May 20, 2024 •Topline interim data from the farudodstat Phase 2a study in AA expected in Q3 2024•Topline data from the TREK-DX trial of eblasakimab expected at the end of 2024•Selection of a dev...

LeoforDharma

May 6 04:03

Opinion

$Aslan Pharmaceuticals (ASLN.US)$
Hi @Trytosaveabit May i kindly get ur opinion/ analysis on this company (No advise on buy sell).

No comment yet